FRA/NOT (FRA/NOT)

Frankfurt Stock Exchange: FRA/NOT · EUR

€139

+1.40 (+1.0%)· Recorded snapshot

Market cap	263.4B
Revenue (ttm)	50.5B
Net income (ttm)	8.8B
EPS (ttm)	€4.73
P/E (trailing)	29.3x
P/E (forward)	16.1x
Dividend	€4.10 (2.96%)
Volume	367

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 50.5B
Net income (ttm): 8.8B
EPS (ttm): €4.73
P/E (trailing): 29.3x
P/E (forward): 16.1x
Market cap: 263.4B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E16.1

P25 n/aP50 n/aP75 n/a

Trailing P/E29.3

P25 n/aP50 n/aP75 n/a

ROE24.3

P25 n/aP50 n/aP75 n/a

ROIC19.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All FRA/NOT indicators

Market & fundamental data

Available fields

238

Groups with data

Currency

USD

Showing 238 of 238 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Switzerland
Country code	DE
Earnings date	2026-10-27
Employees	75,267
Employees change	-616
Employees growth	-0.81%
Enterprise value	EUR 299.3B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-10
Fiscal year end	December
Founded	1996
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	CH0012005267
Last earnings date	2026-10-27
Last refreshed	2026-10-28
Last stock split date	2001-05-07
Last stock split type	Forward
Market cap	EUR 263.4B
Next earnings date	2027-02-03
Price	EUR 138.58
Price currency	EUR
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-27
Symbol	fra/NOT
Website	https://www.novartis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	19.87x
Average P/E ratio (3Y)	17.62x
Average P/E ratio (5Y)	17.8x
Earnings yield	3.41%
EV/Earnings	33.89x
EV/EBIT	17x
EV/EBITDA	13.61x
EV/FCF	21.71x
EV/Sales	5.78x
FCF / EV yield	4.61%
FCF yield	5.23%
Forward P/E	16.1x
Graham number	42.65823
Graham upside	-69.22%
Lynch fair value	EUR 23.24
Lynch upside	-83.23%
P/(FCF - SBC) ratio	20.6x
P/(OCF - SBC) ratio	18.48x
P/B ratio	7.96x
P/E ratio	29.33x
P/FCF ratio	19.1x
P/OCF ratio	17.27x
P/S ratio	5.21x
Price/EBITDA ratio	12.43x
Sector forward P/E	14.8x
Sector P/E	39.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	33.98%
EBITDA margin	41.94%
Effective tax rate	20.8%
FCF margin	26.74%
Gross margin	75.21%
Operating margin	33.98%
Pretax margin	22.04%
Profit margin	17.49%
Profit per employee	EUR 117,360
Profitable quarters	106
Profitable years	28
Revenue per employee	EUR 671,141
ROA	10.86%
ROA (5Y)	7.4%
ROCE	23.04%
ROE	24.33%
ROE (5Y)	23.91%
ROIC	19.26%
ROIC (5Y)	17.5%
SBC / revenue	1.98%
Tax / revenue	4.58%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-28.31%
EPS growth (Q)	-68.81%
EPS growth (QoQ)	-63.16%
EPS growth 10Y	6.32%
EPS growth 3Y	12.03%
EPS growth 5Y	3.87%
EPS growth years	1
FCF growth	-20.02%
FCF growth (Q)	-17.79%
FCF growth (QoQ)	-8.09%
FCF growth 3Y	1.3%
FCF growth 5Y	2.63%
Gross profit growth	0.4%
Gross profit growth (Q)	5.89%
Gross profit growth 3Y	8.64%
Gross profit growth 5Y	3.12%
Net income growth	-30.31%
Net income growth (Q)	-69.4%
Net income growth (QoQ)	-63.17%
Net income growth 3Y	8.58%
Net income growth 5Y	0.45%
Net income growth years	1
OCF growth	-17.79%
OCF growth (Q)	-16.25%
OCF growth (QoQ)	-6.44%
OCF growth 10Y	3.71%
OCF growth 3Y	2.64%
OCF growth 5Y	2.66%
Operating income growth	1.26%
Operating income growth (Q)	16.25%
Operating income growth 3Y	19.41%
Operating income growth 5Y	7.48%
Revenue growth	1.76%
Revenue growth (Q)	4.67%
Revenue growth (QoQ)	0.52%
Revenue growth 10Y	1.46%
Revenue growth 3Y	7.75%
Revenue growth 5Y	1.83%
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -1.5B
Depreciation and amortization	EUR 4.1B
EBIT	EUR 17.2B
EBITDA	EUR 21.2B
EPS	EUR 4.73
Financing cash flow	EUR 685.1M
Free cash flow	EUR 13.8B
Free cash flow minus SBC	EUR 12.8B
Gross profit	EUR 38B
Income taxes	EUR 2.3B
Investing cash flow	EUR -16.5B
Net borrowing	EUR 14.6B
Net cash flow	EUR -604.1M
Net income	EUR 8.8B
Operating cash flow minus SBC	EUR 14.3B
Operating income	EUR 17.2B
Revenue	EUR 50.5B
Stock-based compensation	EUR 1B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.56
Book value per share	EUR 17.36
Debt / EBITDA	1.98
Debt / equity	1.29
Debt / FCF	3.09
Goodwill	EUR 24.4B
Interest coverage	12.36
Long-term assets	EUR 77.3B
Long-term liabilities	EUR 40.9B
Net cash (debt)	EUR -34.7B
Net cash / market cap	-13.18%
Net debt / EBITDA	1.64
Net debt / equity	1.05
Net debt / FCF	2.52
Piotroski F-Score	5
Property, plant and equipment	EUR 11B
Shareholders' equity	EUR 33.1B
Tangible book value	EUR -26.2B
Tangible book value per share	EUR -13.88
Total assets	EUR 103.2B
Total cash	EUR 7.8B
Total debt	EUR 42.5B
Total liabilities	EUR 70.1B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.51
Current assets	EUR 25.8B
Current liabilities	EUR 29.2B
Current ratio	0.88
Inventory turnover	2.27
Net working capital	EUR -2.4B
Quick ratio	0.58
Working capital	EUR -3.3B
Working capital turnover	-13.33

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	2.76%
Dividend growth	12.84%
Dividend growth (10Y)	5.15%
Dividend growth (3Y)	8.16%
Dividend growth (5Y)	8.63%
Dividend growth years	4
Dividend payment date	2026-03-12
Dividend payment years	27
Dividend payout frequency	Annual
Dividend per share	EUR 4.10
Dividend yield	2.96%
Ex-dividend date	2026-03-10
Last dividend	EUR 4.10
Payout ratio	90.4%
Shareholder yield	5.72%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 130.62
1D price change	1.02%
1M price change	9.5%
1M total return	9.5%
1W price change	3.45%
1W total return	3.45%
1Y price change	23.1%
1Y return CAGR	26.87%
1Y total return	26.85%
20-day SMA	EUR 131.07
200-day SMA	EUR 131.14
3M price change	1.14%
3M total return	1.14%
50-day SMA	EUR 129.81
50-day SMA vs 200-day SMA	50under200
52-week high	EUR 144.08
52-week high date	2026-03-02
52-week low	EUR 105.36
52-week low date	2025-10-29
6M price change	11.76%
6M total return	11.76%
All-time high	EUR 144.08
All-time high date	2026-03-02
All-time low	EUR 94.56
All-time low date	2025-05-15
Average true range (ATR)	EUR 3.01
Average volume	950.3
Change from 52-week high	-3.82%
Change from 52-week low	31.53%
Change from all-time high	-3.82%
Change from all-time low	46.55%
Change from open	1.26%
Day's gap	-0.23%
Dollar volume	EUR 50,859
High price	EUR 140.60
Low price	EUR 136.86
Monthly RSI	67.58
Open price	EUR 136.86
Position in 52-week range	45.99%
Previous close	EUR 137.18
Price vs 150-day SMA	6.1%
Price vs 20-day SMA	5.73%
Price vs 200-day SMA	5.67%
Price vs 50-day SMA	6.76%
Relative volume	0.39
RSI	63.71
Sharpe ratio	1.1
Sortino ratio	1.75
Volume	367
Weekly RSI	57.45
YTD price change	17.34%
YTD total return	20.92%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.9B
Shares change (QoQ)	-0.47%
Shares change (YoY)	-2.76%
Shares held by insiders	0.11%
Shares held by institutions	36.29%

Deeper analysis on FRA/NOT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this FRA/NOT report

Is a complete FRA/NOT research report available?

No complete published report is available for fra/NOT (FRA/NOT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

FRA/NOT (FRA/NOT)

Price

Financial snapshot

Fair-value bridge

Latest news · FRA/NOT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All FRA/NOT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on FRA/NOT

Frequently asked questions